ArticleJournal of general and family medicine2026
Relative Dose Intensity and Survival Outcomes in Older Adults With Lymphoma: A Single-Center Retrospective Analysis.
Article in Journal of general and family medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment intensity in older adults with lymphoma is often reduced because of frailty, comorbidities, and poor performance status (PS). Whether chronological age or delivered treatment intensity better predicts outcomes remains unclear. Methods: We retrospectively reviewed 79 patients aged ≥ 65 years with newly diagnosed lymphoma initiating first-line therapy. Progression-free survival (PFS) was the primary outcome and overall survival (OS) secondary. Relative dose intensity (RDI) effects were expressed as hazard ratios (HRs) per 10%-point increase. Cox models adjusted for age, sex, Ann Arbor stage, Charlson Comorbidity Index (CCI), and PS; diffuse large B-cell lymphoma (DLBCL) models additionally included the International Prognostic Index (IPI). Results: Median RDI was lower in patients aged ≥ 75 years than in those aged 65-74 years (63.3% vs. 85.4%; Conclusions: Higher RDI was associated with longer PFS in the full cohort and DLBCL subgroup, and with longer OS in DLBCL. RDI may provide prognostic information beyond age and IPI-defined risk but may reflect physiological reserve and treatment tolerance. Prospective validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.